Loading...
XTAI
1762
Market cap61mUSD
Dec 05, Last price  
24.95TWD
1D
-0.99%
1Q
-11.37%
Jan 2017
-7.76%
IPO
-60.46%
Name

Chunghwa Chemical Synthesis & Biotech Co Ltd

Chart & Performance

D1W1MN
XTAI:1762 chart
P/E
36.19
P/S
1.42
EPS
0.69
Div Yield, %
9.62%
Shrs. gr., 5y
-0.51%
Rev. gr., 5y
3.10%
Revenues
1.35b
-35.42%
1,126,848,0001,197,243,0001,200,576,0001,329,584,0001,043,480,000946,704,0001,162,211,0001,198,670,0001,168,248,0001,019,452,0001,156,642,0001,543,589,0001,934,702,0002,117,144,0002,086,440,9991,347,375,000
Net income
53m
-79.98%
245,105,000187,004,000170,994,000175,564,00096,825,00014,592,000308,356,00060,283,00085,766,000234,251,000117,003,000531,873,000400,778,000465,865,000264,909,00053,032,000
CFO
468m
P
462,069,000275,614,000144,843,000268,465,000145,240,00023,081,00079,705,000261,313,000159,339,000234,664,000268,128,000138,235,000219,179,000733,779,000-77,503,000467,654,000
Dividend
Jul 26, 20240.8 TWD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and wholesale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, cardiovascular, and other products, as well as peptide drugs. The company also develops bulk pharmaceutical products, such as anti-anxiety agents, antidiabetics, laxatives, antifungals, antihistamines, antiseptics, antiulcerants, cardiovascular drugs, skeletal, muscle relaxants, hypolipaemics, antineoplastic, antihyperlipedemias, and immunosuppressant products, as well as provides research and development, and contract manufacturing services to new drug developers and generic drug companies. The company was formerly known as China Chemical Synthesis Industry Co., Ltd. Chunghwa Chemical Synthesis & Biotech Co., Ltd. was founded in 1964 and is headquartered in New Taipei City, Taiwan.
URL
http://www.ccsb.com.tw/
IPO date
Dec 10, 2009
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT